-

Barclays plc Investor Update: Robbins LLP Reminds Shareholders of Class Action Against Barclays plc (BCS)

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Barclays plc (NYSE: BCS) American Depository Receipts (ADRs) on a U.S. open market between February 18, 2021 and March 25, 2022, for violations of the Securities Exchange Act of 1934. Barclays is a British universal bank, offering consumer banking and payments services in the United Kingdom, United States, and Europe, as well as global corporate and investment banking services.

If you would like more information about Barclays plc's misconduct, click here.

What is this Case About: Barclays plc (BCS) Had Ineffective Internal Controls over Financial Reporting

According to the complaint, starting on February 18, 2021, BBPLC, a wholly owned subsidiary of Barclays, issued and sold approximately $17.64 billion in unregistered securities over and above the maximum amount of securities registered in two BBPLC shelf registration statements, which was not immediately discovered. The over-issuance and sale of the unregistered securities was a violation of U.S. securities laws and/or SEC regulations.

On March 28, 2022, before the trading market for Barclays ADRs opened for the day, Barclays announced the over-issuance for the first time, that BBPLC had issued approximately $15.2 billion in unregistered securities under an August 2019 shelf registration statement, that BBPLC would commence a rescission offer for those unregistered securities, and that Barclays expected the rescission losses to be c.£450m. In response to this news, on March 28, 2022, the price of Barclays ADRs declined 10.61%, or $0.96 per ADR, from a closing price on March 25, 2022 of $9.05 per ADR to a closing price of $8.09 per ADR on the next trading day.

Then, on July 28, 2022, before the trading market for Barclays ADRs opened for the day, Barclays issued interim financial results for the quarter ending June 30, 2022, and announced for the first time that BBPLC had also over-issued unregistered securities under a second BBPLC shelf registration statement. The July 28, 2022 financial results announcement also informed investors that Barclays had provisioned “£1,592m [approximately $1.940 billion] (December 2021: £220m) related to the overissuance of structured notes and £165m [approximately $201 million] (December 2021: nil) related to liabilities that could be incurred arising out of ongoing discussions in respect of a potential SEC resolution.” On this news the price of Barclays ADRs declined $0.41 per ADR, or 5.2%, to close at $7.48 per ADR on July 28, 2022.

Next Steps: If you acquired shares of Barclay plc ADRs between February 18, 2021 and March 25, 2022, you have until November 22, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Barclays plc settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:BCS

Release Summary
Barclays plc (BCS) Had Ineffective Internal Controls over Financial Reporting
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Reminds Intuit Inc. Investors With Significant Losses of the Opportunity to Lead the the Securities Fraud Class Action Against INTU

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities who purchased or otherwise acquired Intuit Inc. (NASDAQ: INTU ) securities between August 22, 2025 and May 20, 2026, inclusive (the “Class Period”).The lawsuit alleges that Intuit misled investors about the sustainability and growth of its business, including its TurboTax business, and failed to disclose increasing competitive and pricing pressures affecti...

Investor Alert: Robbins LLP Informs Investors of the Wise Group plc Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle compli...
Back to Newsroom